NF-κB mediates resistance toward diverse cancer therapeutics by inhibition of apoptosis, and inhibition of NF-κB sensitizes cancer cells toward anticancer drugs (e.g., doxorubicin and imatinib), cytotoxic phytochemicals (e.g., curcumin), biological agents (e.g., β–IFN and TRAIL), and radiation (Schwartz et al., 1999; Deeb et al., 2004; Bednarski et al., 2008; Chen et al., 2008; Choi et al., 2008; Lounnas et al., 2009; Tracey et al., 2010). The gene discussed is NFKB1; the disease is cancer.